BibbInstruments AB
The answer first
Does BibbInstruments beat the market?
No, BibbInstruments has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 21% of Nordic stocks
- Quality83
- Value21
- Trend4
No. 129 of 195 in healthcare
Max for seven days
Follow BibbInstruments with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 17 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about BibbInstruments
Your first answer is free, no account needed.
Do you own BibbInstruments, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with BibbInstruments and a few more. Free, no card.
Super Stock+45.9%In short
- BibbInstruments has fallen 88.4% over the past year, including dividends.
- Overall, BibbInstruments ranks better than 21% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 94.7%. The price is 97.7% below its peak now.
What do analysts think of BibbInstruments?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 21% of Nordic stocks.
No. 129 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 44 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.01
- Return on equityProfit divided by equity−28.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 99 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity0.8
- P/SPrice divided by sales56.5
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 185 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−42.5%
- 6 months−30.5%
- 9 months−84.4%
- 12 months−88.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About BibbInstruments
BibbInstruments AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
BiBBInstruments AB, a medical technology company, develops and markets electrically powered endoscopic biopsy systems in the United States and Europe. The company offers EndoDrill which enables tissue sampling, with the aim of improving diagnostics in several common cancers, including those affecting the pancreas, stomach, liver, lungs, and urinary bladder. It also provides EndoDrill GI which used for endoscopic ultrasound; EndoDrill EBUS is used in the airways during endobronchial ultrasound (EBUS); and EndoDrill URO that is used with a standard cystoscope for sampling of muscle-invasive bladder cancer. The company was incorporated in 2013 and is headquartered in Lund, Sweden.


See the full analysis of BibbInstruments.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card